



CCM DUOPHARMA BIOTECH BERHAD
(formerly known as Duopharma Biotech Bhd) (524271-W)

(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 30 SEPTEMBER 2006

Group	Reserves					Total RM '000
	Share Capital RM '000	Treasury Shares RM' 000	Share Premium RM '000	Revaluation Surplus RM '000	Retained Profit RM '000	
At 1 January 2006						
As previously reported	69,679	(1,578)	13,497	1,662	54,610	137,870
Derecognition of negative goodwill	-	-	-	-	2,885	2,885
As restated	69,679	(1,578)	13,497	1,662	57,495	140,755
Net profit for the period	-	-	-	-	22,738	22,738
Total recognised income for the period	-	-	-	-	22,738	22,738
Issuance of new ordinary shares: -Employees Share Option Scheme	37	-	136	-	-	173
2005 final dividend [35% (17.5 sen) per share less tax of 28%]	-	-	-	-	(17,485)	(17,485)
2006 interim dividend [14% (7.0 sen) per share less tax of 28%]	-	-	-	-	(6,994)	(6,994)
At 30 September 2006	69,716	(1,578)	13,633	1,662	55,754	139,187

←----- Reserves ----->
 <----- Non-distributable -----> Distributable

Group	Share Capital RM '000	Treasury Shares RM' 000	Share Premium RM '000	Revaluation Surplus RM '000	Retained Profit RM '000	Total RM '000
At 1 January 2005	66,000	-	106	-	36,862	102,968
Revaluation of freehold land & buildings	-	-	-	1,662	-	1,662
Net gains recognised directly in equity	-	-	-	1,662	-	1,662
Net profit for the period	-	-	-	-	23,513	23,513
Total recognised income for the period	-	-	-	1,662	23,513	25,175
2004 final dividend (6 sen per share less tax of 28%)	-	-	-	-	(5,765)	(5,765)
Share buy-back	-	(1,578)	-	-	-	(1,578)
Issuance of new ordinary shares: -Employees Share Option Scheme	3,679	-	13,391	-	-	17,070
At 31 December 2005	69,679	(1,578)	13,497	1,662	54,610	137,870

(The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2005 and the accompanying explanatory notes attached to the interim financial statements.)



CCM DUOPHARMA BIOTECH BERHAD
(formerly known as Duopharma Biotech Bhd) (524271-W)
(Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED CASH FLOW STATEMENT
FOR THE PERIOD ENDED 30 SEPTEMBER 2006

	30 Sept 2006	30 Sept 2005
	RM '000	RM '000
Cash generated from operations:	28,327	20,958
Income taxes paid	(7,864)	(3,802)
Net cash generated from operating activities	20,463	17,156
Net cash used in investing activities	(2,040)	(4,122)
Cash generated from financing activities		
Dividend paid	(24,479)	(5,765)
Share buy back	-	(1,578)
Unallocated ESOS application money	-	232
Proceed from issuance of shares	173	14,934
Net cash (used in) / generated from financing activities	(24,306)	7,823
Net (decrease) / increase in cash and cash equivalents	(5,883)	20,857
Cash and cash equivalents as at 1 January	52,406	25,992
Cash and cash equivalents as at 30 Sept (I)	46,523	46,849

(I) Cash and cash equivalents comprise:

	RM '000	RM '000
Cash and bank balances	3,971	14,659
Fixed deposits placed with licensed financial institutions	42,552	32,190
	46,523	46,849

(The Condensed Consolidated Cash Flow Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2005 and the accompanying explanatory notes attached to the interim financial statements.)